Pfizer, a pharmaceutical corporation, through its Hospital business, agreed to acquire Arixa Pharmaceuticals, a pharmaceutical company. Financial terms were not disclosed. “Through this acquisition, Pfizer will advance the development program for Arixa’s leading asset, ARX-1796. We are excited by the potential benefits ARX-1796 may provide to patients and the healthcare system overall, potentially allowing patients to leave the hospital earlier or avoid the need for hospital admission altogether,” Annaliesa Anderson, Pfizer Vice President and Chief Scientific Officer Bacterial Vaccines and Hospital.